The use of p16/Ki-67 dual staining technology on cervical cytology of patients undergoing a LLETZ procedure

被引:3
|
作者
Packet, Bram [1 ]
Poppe, Willy [1 ]
Weynand, Birgit [2 ]
Vanherck, Miet [2 ]
机构
[1] Univ Hosp Leuven, Dept Gynaecol, Herestr 49, Leuven, Belgium
[2] Univ Hosp Leuven, Dept Pathol, Herestr 49, Leuven, Belgium
关键词
CINtec PLUS (R) cytology test; Diagnostic cytology; Conisation; Triage; p16/Ki-67 dual stain cytology; HPV-POSITIVE WOMEN; HUMAN-PAPILLOMAVIRUS; CANCER PRECURSORS; PAPANICOLAOU TEST; PAP CYTOLOGY; FOLLOW-UP; TRIAGE; COLPOSCOPY; RISK; TERMINOLOGY;
D O I
10.1016/j.ejogrb.2018.06.025
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives: The main objective of this prospective observational study was to investigate the diagnostic performance of the p16/Ki-67 dual stain technique (DST) for detecting CIN 2+ in a LLETZ referral setting. Test performances were compared with HR-HPV testing and Pap cytology. Methods: All patients referred for a LLETZ procedure were candidates for participation in this trial. A total of 110 patients were enrolled between October 2016 and March 2017. From each participant, a cervical cytology sample was obtained before the onset of the LLETZ procedure. On each sample, the dual stain technique (Roche CINtec PLUS (R) test), Pap cytology and an HPV DNA assay (identifying 17 different HPV types) were performed. Results: The overall disease prevalence of CIN 2+ was 56%. The mean age was 41 years, with 38% of patients being younger than 35 years. The overall sensitivity and specificity of the dual stain technique for detecting CIN 2+ was 94% (95% CI: 84.30-98.21%) and 58% (95% CI: 43.21-72.93%) respectively with a PPV of 74% (95% CI: 67.34-80.31%) and a NPV of 88% (95% CI: 72.48-94.90%). HR-HPV testing results in a similar sensitivity of 92% (95% CI: 82.17-97.33%) but considerable lower specificity of 21% (95% CI: 11.17-33.35%) compared to the dual stain technique. At an ASCUS or worse threshold, Pap cytology had the lowest sensitivity of 89% (95% CI 78.11-95.34%) compared to dual staining and HR-HPV testing. Specificity was better (48% with 95% CI of 33.29-62.81%) than that of HR-HPV testing but not as good as the DST. Conclusion: p16/Ki-67 dual staining provides high sensitivity and improved specificity compared to HR-HPV testing and Pap cytology for detecting CIN 2+, making it an interesting tool for identifying relevant disease in patients referred for a LLETZ procedure. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:191 / 196
页数:6
相关论文
共 50 条
  • [41] Correlation Between p16/Ki-67 Expression and the Grade of Cervical Intraepithelial Neoplasias
    Mandal, Rananjit
    Ghosh, Ishita
    Banerjee, Dipanwita
    Mittal, Srabani
    Muwonge, Richard
    Roy, Chinmayi
    Panda, Chinmay
    Vernekar, Manisha
    Frappart, Lucien
    Basu, Partha
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2020, 39 (04) : 384 - 390
  • [42] CLINICAL VALUE OF P16/KI-67 IMMUNOHISTOCHEMICAL DUAL-STAINING IN THE GRADING DIAGNOSIS OF PATIENTS WITH ABNORMAL CERVICAL THINPREP CYTOLOGIC TEST SCREENING
    Bian, Meina
    Wang, Nan
    Liu, Qing
    ACTA MEDICA MEDITERRANEA, 2022, 38 (06): : 4221 - 4225
  • [43] Comparative Assessment of p16/Ki-67 Dual Staining Technology for cervical cancer screening in women living with HIV (COMPASS-DUST)-Study protocol
    Okunade, Kehinde C.
    Badmos, Kabir Y.
    Okoro, Austin A.
    Ademuyiwa, Iyabo A.
    Oshodi, Yusuf A.
    Adejimi, Adebola
    Awolola, Nicholas
    Ozonu, Oluchi
    Adelabu, Hameed S.
    Olorunfemi, Gbenga A.
    Akanmu, Alani I.
    Banjo, Adekunbiola S.
    Anorlu, Rose
    Berek, Jonathan
    PLOS ONE, 2023, 18 (01):
  • [44] Meta-analysis on the performance of p16/Ki-67 dual immunostaining in detecting high-grade cervical intraepithelial neoplasm
    Sun, Meng
    Shen, Yang
    Ren, Mu-Lan
    Dong, Yi-Min
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S587 - S593
  • [45] Diagnostic performance of p16/Ki-67 dual immunostaining at different number of positive cells in cervical smears in women referred for colposcopy
    Gajsek, Ursula Salobir
    Dovnik, Andraz
    Takac, Iztok
    Ivanus, Urska
    Jerman, Tine
    Zatler, Simona Sramek
    Fokter, Alenka Repse
    RADIOLOGY AND ONCOLOGY, 2021, 55 (04) : 426 - 432
  • [46] Comparison of HPV 16/18 Genotyping and p16/Ki67 Dual Staining for Detection of High-Grade Cervical Lesion in Patients with Low-Grade Cervical Smears
    Chadha, Saloni
    Gandhi, Gauri
    Hedau, Suresh T. T.
    Gupta, Ruchika
    JOURNAL OF OBSTETRICS AND GYNECOLOGY OF INDIA, 2023, 73 (03) : 248 - 253
  • [47] The p16/ki-67 assay is a safe, effective and rapid approach to triage women with mild cervical lesions
    Magkana, Maria
    Mentzelopoulou, Panagiota
    Magkana, Ekaterini
    Pampanos, Andreas
    Daskalakis, Georgios
    Domali, Ekaterini
    Rodolakis, Alexandros
    Pappa, Kalliopi
    PLOS ONE, 2021, 16 (06):
  • [48] Approaches to triage optimization in HPV primary screening: Extended genotyping and p16/Ki-67 dual-stained cytology-Retrospective insights from ATHENA
    Stoler, Mark H.
    Baker, Ed
    Boyle, Sean
    Aslam, Shagufta
    Ridder, Ruediger
    Huh, Warner K.
    Wright, Thomas C., Jr.
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (09) : 2599 - 2607
  • [49] Validation of an on-chip p16ink4a/Ki-67 dual immunostaining cervical cytology system using microfluidic device technology
    Hashimoto, Kei
    Kumagai, Tomoo
    Nomura, Kyosuke
    Miyagawa, Yuko
    Tago, Saori
    Takasaki, Kazuki
    Takahashi, Yuko
    Nishida, Haruka
    Ichinose, Takayuki
    Hirano, Mana
    Hiraike, Haruko
    Wada-Hiraike, Osamu
    Sasajima, Yuko
    Kim, Soo Hyeon
    Nagasaka, Kazunori
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [50] p16/Ki-67 dual staining as a predictive value for cervical cancer compared to other conventional triage tools: a descriptive literature review
    Bedon, Ana Acosta
    Delgado-Lopez, Dayanara
    Ochoa-Aviles, Cristina
    Rivas-Parraga, Roque
    Crespo, Bernardo Vega
    Verhoeven, Veronique
    Neira, Vivian Alejandra
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2024, 45 (04) : 1 - 15